**Maraviroc**  
Item No. 14641

**CAS Registry No.:** 376348-65-1  
**Formal Name:** 4,4-difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-cyclohexanecarboxamide

**Synonyms:** Celsentri, Selzentry, UK 427857

**MF:** C_{29}H_{41}F_{2}N_{5}O

**FW:** 513.7

**Purity:** ≥98%

**Stability:** ≥2 years at -20°C

**Supplied as:** A crystalline solid

**Laboratory Procedures**

For long term storage, we suggest that maraviroc be stored as supplied at -20°C. It should be stable for at least two years.

Maraviroc is supplied as a crystalline solid. A stock solution may be made by dissolving the maraviroc in the solvent of choice. Maraviroc is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of maraviroc in these solvents is approximately 25, 3.3, and 5 mg/ml, respectively.

Maraviroc is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, maraviroc should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Maraviroc has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Maraviroc is an antagonist of the C-C chemokine receptor type 5 (CCR5), inhibiting binding of the ligand RANTES with an IC_{50} value of 1.4 nM.1 Because human immunodeficiency virus (HIV) uses CCR5 to enter monocytes and macrophages, maraviroc inhibits HIV-1 replication in CCR5-expressing cells (IC_{50} = 2.8 nM).1 The pharmacokinetics of maraviroc in healthy male subjects have been delineated.2

**References**


**Related Products**

For a list of related products please visit: [www.caymanchem.com/catalog/14641](http://www.caymanchem.com/catalog/14641)